The reality behind the rhetoric: How European policies risk harming access to generic medicines in developing countries

Journal of Generic Medicines

Volumn 8, Issue 1, 2011, Pages 14-22

  Arkinstall, James ^a   Childs, Michelle ^b   Menghaney, Leena ^b   Ford, Nathan ^a   Von Schoen Angerer, Tido ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Knowledge Ecology International ^*  (United Kingdom)

Author keywords

Access to medicines; ACTA; data exclusivity; Free Trade Agreements; HIV AIDS; Intellectual property

Indexed keywords

AMOXICILLIN; ANTIRETROVIRUS AGENT; GENERIC DRUG; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONSUMER ADVOCACY; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; JURISPRUDENCE; LAW ENFORCEMENT; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; PUNISHMENT; RIGHT TO LIFE;

EID: 80054933781     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/jgm.2011.1     Document Type: Article

References (28)

1. Creese , A. , Floyd , K. , Alban , A. and Guinness , L. ( 2002 ) Cost-effectiveness of HIV/AIDS interventions in Africa: A systematic review of the evidence. Lancet 11,359 (9318) : 1635-1643.
2. Marseille , E. , Hofmann , P. B. and Kahn , J. G. ( 2002 ) HIV prevention before HAART in sub-Saharan Africa. Lancet 25,359 (9320) : 1851-1856. (Pubitemid 34607065)
3. M é decins Sans Fronti è res. (2010 ) Untangling the web of antiretroviral price reductions , 13th edn. http://utw.msfaccess.org , accessed 1 November 2010.
4. WHO, UNAIDS, UNICEF. ( 2010 ) Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector. Progress report 2010, http://www.who.int/hiv/pub/2010progressreport/report/en/index.html , accessed 1 November 2010.
5. t Hoen , E. (2009) The Global Politics of Pharmaceutical Monopoly Power. Drug Patents, Access, Innovation and the Application of the WTO Doha Declaration on TRIPS and Public Health http://www.msfaccess.org/main/access-patents/the- globalpolitics-of-pharmaceutical-monopoly-power-byellen-t-hoen/. Amsterdam: AMB Publishers , accessed 1 November 2010.
6. t Hoen , E. (2002 ) TRIPS, pharmaceutical patents and access to essential medicines: A long way from Seattle to Doha Chicago Journal of International Law 3(1) 27-48.
7. IPR Chapter of India-EU Broad-based Trade and Investment Agreement, 23 April 2010, preliminary consultation draft, http://www.ip-watch.org/weblog/2010/ 09/03/lack-of-transparency-ineu-india-fta-talks-spurs-requests-for-halt/ , accessed 1 November 2010.
8. Anti-Counterfeiting Trade Agreement Final Text, 3 December 2010, http://trade.ec.europa.eu/doclib/ docs/2010/december/tradoc-147079.pdf , accessed 30 December 2010.
9. Tailor , L. ( 2010 ) EU pledge to India over generics seizures. Pharma Times , 14 December, http://www.pharmatimes.com/Article/10-12-14/EU-pledge-to- India-over-generics-seizures.aspx , accessed 30 December 2010.
10. Letter by EC Commissioner Karel de Gucht to Tido von Schoen-Angerer, MSF 25 May 2010 http://trade.ec.europa.eu/doclib/docs/2010/may/tradoc-146192.pdf accessed 1 November 2010.
11. World Health Organization. ( 2004 ) Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. Geneva, http://www.who.int/medicines/services/ expertcommittees/pharmprep/QAS04-093Rev4-final.pdf , accessed 1 November 2010.
12. Abbott , F. and Dukes , G. ( 2009 ) Global Pharmaceutical Policy. Ensuring Medicines for Tomorrow's World. Cheltenham, UK: Edward Elgar Publishing
13. International Federation of Pharmaceutical Manufacturers Associations. ( 2000 ) Encouragement of new clinical drug development: The role of data exclusivity. Geneva, http://www.ifpma.org/documents/NR643/DataExclusivity-2000. pdf , accessed 1 November 2010.
14. Correa , C. ( 2002 ) Protection of data submitted for the registration of pharmaceuticals: Implementing the Standards of the TRIPS Agreement. South Centre, http://www.southcentre.org/index.php?option=com-content & view=article & id=68%3 A protection-of-data-submitted-for-the- registrationof-pharmaceuticals-implementing-the-standards-ofthe-trips-agreement & catid=41%3Ainnovationtechnology-and-patent-policy & Itemid=67 & lang=en , accessed 1 November 2010
15. Commission on Intellectual Property Rights, Innovation and Public Health. ( 2006 ) Public health, innovation and intellectual property rights: Report of the Commission on intellectual property rights, innovation and public health. WHO, Geneva, http://www.who.int/intellectualproperty/documents/thereport/ ENPublicHealthReport.pdf , accessed 1 November 2010.
16. Timmermans , K. ( 2007 ) Monopolizing clinical trial data: Implications and trends. PLoS Med 4 (2) : e2 , http://www.plosmedicine.org/article/ info%3Adoi%F10.1371%2Fjournal.pmed.0040002.
17. Oxfam and Health Action International. ( October 2009 ) Trading away access to medicines. How the European Union's trade agenda has taken a wrong turn , http://www.oxfam.org/sites/www.oxfam.org/fi les/bp-trading-away-access- to-medicines.pdf.
18. MSF Letter to EC Trade Commissioner on EUIndia FTA, 6 April 2010, http://www.msfaccess.org/fi leadmin/user-upload/medinnov-accesspatents/ MSF%20letter%20to%20Trade%20Commissioner%20April%202010.pdf , accessed 1 November 2010.
19. Letter by EC Commissioner Karel de Gucht to Tido von Schoen-Angerer, MSF 25 May 2010 http://trade.ec.europa.eu/doclib/docs/2010/may/tradoc-146192.pdf accessed 1 November 2010.
20. MSF Letter to EC Trade Commissioner on EUIndia FTA, 8 November 2010, http://www.msfaccess.org/fi leadmin/user-upload/medinnov-accesspatents/2%20- %20MSF%20open%20letter%20to%20Commissioner%20de%20Gucht%20Nov%202010%20FINAL-01. pdf
21. Letter by EC Commissioner Karel de Gucht to MSF, 7 December 2010, http://trade.ec.europa.eu/doclib/docs/2010/december/tradoc-147167.pdf.
22. Global Strategy and Plan of Action for Public Health, Innovation and Intellectual Property. World Health Assembly Resolution 61.21, http://apps.who.int/gb/ebwha/pdf-fi les/A61/A61-R21-en.pdf , accessed 29 December 2010.
23. Council of the European Union. ( 2010 ) Council conclusions on the EU role in Global Health. 3011th Foreign Affairs Council meeting, Brussels, 10 May 2010, http://onetec.be/global-health/doc/ Council%20Conclusions%20Global%20Health%20May%202010.pdf , accessed 30 December 2010.
24. European Parliament Resolution of 12 July 2007 on the TRIPS Agreement and access to medicines, http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-// EP//TEXT+TA+P6-TA-2007-0353+0+DOC+XML+V0//EN , accessed 30 December 2010
25. Asia Pacifi c Network of People Living with HIV/AIDS (APN+). People living with HIV call out EU hypocrisy on MDGs as it pushes FTAs , http://www.bilaterals.org/spip.php?article18216 , accessed 1 November 2010.
26. M é d é cins Sans Fronti é rs. ( 2010 ) MSF Statement regarding the 2010 special 301 review. 3 March 2010, http://www.msfaccess.org/main/access-patents/msf-s-statement-regarding-the-2010- special-301-review/ , accessed 1 November 2010.
27. The National Union of Public and General Employees (NUPGE) statement regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA). 25 October 2010, http://nupge.ca/content/3681/nupge-concernedbig-pharma- trying-sway-ceta-negotiations-attemptfatten-profi ts , accessed 1 December 2010.
28. Waning , B. , Diedrichsen , E. and Moon , S. ( 2010 ) A lifeline to treatment: The role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. Journal of the International AIDS Society 13 : 35 , doi:10.1186/1758-2652-13-35, http://www.jiasociety.org/content/13/1/35 , accessed 1 November 2010.